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ABSTRACT 1 
 2 
Background 3 
 4 
Pharmacy has experienced both incomplete professionalization and 5 
deprofessionalization.  Since the late 1970s, a concerted attempt has been 6 
made to re-professionalize pharmacy in the UK through role extension – a key 7 
feature of which has been a drive for greater pharmacy involvement in public 8 
health.  However, the continual corporatization of the UK community 9 
pharmacy sector may reduce the professional autonomy of pharmacists and 10 
may threaten to constrain attempts at reprofessionalization. 11 
 12 
Objectives 13 
 14 
The objectives of the research: to examine the public health activities of 15 
community pharmacists in the UK; to explore the attitudes of community 16 
pharmacists towards recent relevant UK policy and barriers to the 17 
development of their public health function; and, to investigate associations 18 
between activity, attitudes and the type of community pharmacy worked in 19 
(e.g. supermarket, chain, independent). 20 
 21 
Methods 22 
 23 
A self-completion postal questionnaire was sent to a random sample of 24 
practicing community pharmacists, stratified for country and sex, within Great 25 
Britain (n=1998), with a follow-up to non-responders 4 weeks later. Data were 26 
analyzed using SPSS (v12.0). A final response rate of 51% (n=1023/1998) 27 
was achieved. 28 
 29 
Results 30 
 31 
The level of provision of emergency hormonal contraception on a patient 32 
group direction (PGD), supervised administration of medicines and needle 33 
exchange schemes was lower in supermarket pharmacies than in the other 34 
types of pharmacy.  Respondents believed that supermarkets and the major 35 
multiple pharmacy chains held an advantageous position in terms of attracting 36 
financing for service development despite suggesting that the premises of 37 
such pharmacies may not be the most suitable for the provision of such 38 
services. 39 
 40 
Conclusions 41 
 42 
A mixed market in community pharmacy may be required to maintain a 43 
comprehensive range of pharmacy-based public health services and provide 44 
maximum benefit to all patients.  Longitudinal monitoring is recommended to 45 
ensure that service provision is adequate across the pharmacy network. 46 
47 
 2
FOOTNOTES 48 
 49 
a Several letters and emails were sent to the PSNI asking for the required 50 
registration information. However, no response was forthcoming therefore 51 
Northern Irish pharmacists were removed from the sample. 52 
 53 
b The services listed are commonly perceived, as was identified in pilot 54 
studies, to be the “public health services” that pharmacy provides. The 55 
authors in no way claim that all the listed services are “public health services” 56 
in the widest sense of the new public health agenda. 57 
 58 
59 
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BACKGROUND 60 
 61 
In the United Kingdom (UK), community pharmacists have often been 62 
described as the most accessible of health professionals.1-3  This accessibility 63 
can, at least in part, be attributed to the operation of community pharmacies in 64 
a retail environment.  Pharmacies can only continue to function while they are 65 
profitable.  This context has fostered a tension between the desire of 66 
pharmacists to provide a health service and the necessity to operate a 67 
profitable business. 68 
 69 
The corporatization of community pharmacy 70 
 71 
Historically, most community pharmacies in the UK were owned by self-72 
employed community pharmacists.  However, this pattern of ownership has 73 
been altered markedly by the takeover of independent pharmacies by larger 74 
pharmacy chains and, most recently, by supermarkets (at the time of writing 75 
less than 42% of pharmacies in England and Wales are now part of chains of 76 
5 or fewer outlets compared to 66% in 1994 – see Figure 1).4 5  This growing 77 
‘corporatization’ of the community pharmacy sector has seen multiple 78 
pharmacy chains, and now supermarkets, assume a position of predominance 79 
in terms of the provision of pharmaceutical services. 80 
 81 
Figure 1 shows an uncharacteristic increase in the number of pharmacy 82 
outlets between the years 2004-2005 and 2006-2007 (an increase of 398 83 
outlets for the two years compared to a net decrease of 68 pharmacies for the 84 
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previous 10 years).  While the number of independents fell by 321, the 85 
number of chains increased by 719.  In 2003, the Office of Fair Trading (OFT) 86 
– a Government department which is ostensibly responsible for making 87 
markets work well for consumers – published its report “The control of entry 88 
regulations and retail pharmacy services in the UK”.6  The OFT recommended 89 
the abolition of regulations governing the awarding of National Health Service 90 
(NHS) dispensing contracts which enable a retail pharmacy outlet to dispense 91 
NHS prescriptions (approximately 80% of the average community pharmacy’s 92 
turnover is generated by NHS prescription business).7  The regulations had 93 
been in place since 1987 and had ensured the maintenance of outlets at a 94 
relatively steady level ever since (see Figure 1), thus ensuring a fairly uniform 95 
community pharmacy network throughout the UK. 96 
 97 
Of 542 applications awarded contracts from 2005-06 to 2006-07 under the 98 
exemptions introduced in response to the OFT report, 15% (n=84) were 99 
awarded to pharmacies meeting the criteria for out of town, large shopping 100 
developments (that is developments over 15,000 square meters – which 101 
applies to many supermarkets) and 77% (n=415) were awarded to 102 
pharmacies proposing to open for 100 or more hours a week (again, 103 
applicable, but not exclusive to, supermarkets).5 8  These data suggest that 104 
the relaxations to the Control of Entry Regulations have further facilitated the 105 
development of the corporate pharmacy sector. 106 
 107 
Corporatization and professionalism 108 
 109 
 5
As an organization, such as a pharmacy chain, grows in complexity, it is 110 
forced to adopt distinct working practices in order to operate economically, 111 
effectively and competitively.  Profits are maximized by the rationalization of 112 
products and services.  Ritzer (2000) has coined the term “McDonaldization” 113 
to illustrate that the policies and practices adopted for efficient, routinized 114 
production of fast food pervade into other organizations, including those in the 115 
healthcare sector.9  Harding and Taylor (2000) have underlined how the four 116 
dimensions of rationality highlighted by Ritzer (2000), namely Efficiency, 117 
Predictability, Calculability and Control, are evident in corporate pharmacies in 118 
the UK.9 10  119 
 120 
Efficiency is achieved through standardisation and rationalisation of products 121 
and services.  For example, there is a production line approach to dispensing 122 
with technicians each completing a small part of the process, a process set to 123 
become further rationalised by new technologies such as electronic transfer of 124 
prescriptions and robotic dispensing systems.  Predictability is achieved by 125 
standardising services, products and pack sizes, so that all outlets – all of a 126 
uniform design – offer identical “experiences”.  Employees follow written 127 
protocols to ensure uniformity of service – routinizing even interactions 128 
between pharmacists and clients.11  Calculability comes from the 129 
commodification of medicines (i.e. medicines are sold as commodities on the 130 
basis of cost rather than on quality and efficacy).  Control is exerted by 131 
minimising the skilled activities of the workforce.  Employees undertake 132 
simple, clearly defined tasks in accordance with written procedures whilst 133 
technology is used whenever possible.10   134 
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 135 
The changing patterns of pharmacy ownership have implications for 136 
pharmacy’s claim to professional status.  The predominance of the multiple 137 
pharmacy chains and supermarkets has led to a proportionate increase in 138 
employee pharmacists at the expense of independent pharmacist-proprietors.  139 
With an increasing number of pharmacists being recruited as employees of 140 
major corporations, it is argued that the professional autonomy of these 141 
pharmacists is challenged.  As Harding and Taylor (1997) state:  142 
 143 
“Successful large bureaucratic organizations require rational and 144 
routinized procedures for maximizing efficiency, and this is reflected in 145 
their delivery of rationalized, standardized pharmaceutical services 146 
dictated by company policies.  Thus the autonomy of pharmacists 147 
employed in such organizations to practice discretion in their 148 
occupation is precluded” (p556).12 149 
 150 
The rationalization imposed by corporate pharmacy has been such that some 151 
pharmacists have non-pharmacist line managers and may be required to 152 
undertake ‘general shop duties’.13  It is argued that a future breed of 153 
“McPharmacists” may be subjected to de-skilling and ultimately perform solely 154 
routinized activities for comparatively little remuneration.10 14 155 
 156 
However, corporatization was just one of a series of developments that 157 
threatened the professionalism of community pharmacists.  Throughout the 158 
twentieth century community pharmacy was subjected to widespread erosion 159 
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of its traditional functions.  Massive increases in prescription volumes and the 160 
transference of the responsibility for drug manufacture from pharmacists to 161 
the pharmaceutical industry – allied to technological advances such as the 162 
introduction of pharmacy computer systems and the repackaging of drugs 163 
from loose pots of one thousand or more into standardized original packs (of 164 
28 days duration for example) – have led to the automation of tasks within 165 
pharmacy which has, in turn, undermined the traditional basis for its claim to 166 
professional status.15 16  Additionally, the trend of making drugs increasingly 167 
available for purchase from non-pharmacy outlets (such as petrol filling 168 
stations and grocers), reduces the drugs to a commodity, with the connotation 169 
that no associated ‘expert’ supervision and advice is required.17  By the late 170 
1970s there was recognition that community pharmacy in the UK was in 171 
trouble.  Community pharmacists found themselves over-trained for what they 172 
did and under-utilized in relation to what they knew.18   173 
 174 
Reprofessionalization 175 
 176 
The profession's response to the loss of function and the resultant stress and 177 
role ambiguity was ‘role extension’ as part of a movement toward 178 
‘reprofessionalization’.15 19  The process of reprofessionalization manifested 179 
itself primarily in a gradual shift away from the technical paradigm (i.e. drug 180 
procurement, storage and compounding) toward an entirely different 181 
paradigm: one that emphasizes a disease and patient-orientated approach to 182 
pharmaceutical decisions.19 20 183 
 184 
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Anderson (2002) argues that, in the UK, a significant part of the 185 
reprofessionalization of pharmacy took the form of a reclaiming of the 186 
pharmacists’ traditional role in health promotion.21  Indeed, the gamut of 187 
pharmacy policy documents published in the UK since the mid-1980s would 188 
appear to support this thesis.22-27  In addition to the pharmacists’ role in health 189 
promotion, a number of health improving or harm reducing services have 190 
been categorized, certainly within the profession, as constituting pharmacy’s 191 
public health function (see Table 1).  Recent developments have seen an 192 
expansion in the provision of diagnostic testing (e.g. blood pressure, diabetes 193 
etc.) through pharmacies, a function set to be reinforced by the provision of a 194 
nationwide (England) programme of ‘vascular health checks’.27  Furthermore, 195 
changes in policy, law and contractual frameworks have led to the 196 
reclassification of a growing number of prescription-only medicines (POMs – 197 
preparations that are available only on a prescription issued by an appropriate 198 
practitioner) as pharmacy medicines (“P” medicines – preparations which are 199 
available in a pharmacy without a prescription, under the supervision of a 200 
pharmacist), the introduction of patient group directions (PGDs) to allow 201 
pharmacy supply of POMs to specific patient groups without the requirement 202 
of a physician’s prescription and the introduction of a limited number of 203 
pharmacist-prescribers – first on a supplementary basis to physicians, but 204 
now also as independent prescribers.   205 
 206 
In 1994, health promotion became a contractual obligation for community 207 
pharmacy with remuneration being received for the display of health 208 
promotion materials (posters and leaflets).  The obligation for pharmacists to 209 
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be involved in health promotion was consolidated in the ‘new’ (2005) 210 
contractual framework for England and Wales with ‘public health’ (in terms of 211 
healthy lifestyle promotion) designated as an ‘essential’ service obliging each 212 
pharmacy to take part in six public health campaigns (again, principally health 213 
promotion), coordinated by the local Primary Care Organization (PCO – local 214 
NHS organization), each year.  Furthermore, many services that 215 
contemporary debate designates as contributing towards pharmacy’s public 216 
health function (i.e. services for drug misusers), are included in the ‘enhanced’ 217 
services category introduced under the new contract and therefore provision 218 
of these services by pharmacy is dependent upon the commissioning 219 
decisions of local PCOs.28  220 
 221 
Enhanced service provision under the new pharmacy contract. The 222 
development of the public health function of community pharmacists, as part 223 
of the extended role, has been focused on individual-level intervention and 224 
service provision.  Pharmacy has been criticized for this focus and for a 225 
reluctance to engage with the arguments surrounding the structural and 226 
political causes of ill health within communities.29  However, no practical 227 
suggestions of how pharmacy can contribute at a more macroscopic level are 228 
suggested and it is difficult to envisage how pharmacy’s public health function 229 
could develop any differently. 230 
 231 
As stated previously, since 2005, many of the services that contemporary 232 
debate in the UK deems as pharmacy’s ‘public health services’ have been 233 
located in the ‘enhanced’ services category of the pharmacy contract (i.e. 234 
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services which have to be commissioned by local PCOs on the basis of need).  235 
While little data are currently available on enhanced service provision, the 236 
data that are in the public realm suggest that the commissioning of enhanced 237 
pharmaceutical services has been modest.30 31  No data are available to 238 
indicate variations in service provision under the new contract between the 239 
different types of pharmacy (e.g. supermarket, multiple, independent) 240 
although one study suggests that pharmacists working in large, national 241 
companies were most enthusiastic about the new contract.32 242 
 243 
Limits to reprofessionalization presented by corporatization 244 
 245 
As community pharmacists have sought to develop an extended role through 246 
the provision of health improvement/harm reduction services, there has been 247 
some opposition from General Practitioners (GPs – ‘community physicians’) 248 
who have countered what they perceive to be encroachment from 249 
pharmacists onto both their economic and professional turf, viewing this as a 250 
threat to their status as the predominant profession in the medical division of 251 
labour.18 33  However, Edmunds and Calnan (2001) believe that the role 252 
extension of community pharmacists is more accurately interpreted as a bid 253 
for survival rather than any threat to the dominance of GPs.34 254 
 255 
However, opposition to the extended role as a reprofessionalization strategy is 256 
in some part fuelled by the corporatization of the community pharmacy sector.  257 
Denzin and Mettlin (1968) argue that the commercial interests of pharmacy 258 
owners are inconsistent with the altruistic attitude of the service ideal of 259 
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professions.35  It has to be acknowledged however, that all professions are 260 
paid – some, such as lawyers and physicians, are generally paid handsomely.  261 
What distinguishes these professions from pharmacy is that a pharmacist-262 
proprietors’ remuneration is based on trading as opposed to the levy of a fee.  263 
Community pharmacists operate in a commercial environment and, as 264 
traders, their raison d’être is to sell – not whether the customer requires or is 265 
in anyway poorly served by the sale.  Physicians are likely to be unwilling to 266 
work in partnership with individuals who they believe have a focus on profit-267 
generation: a focus which may possibly be detrimental to ‘their’ patients.36-39  268 
To compound this, pharmacy has a uniprofessional culture which reinforces 269 
the professional isolation of pharmacists by understating the value of 270 
partnerships.40 271 
 272 
Jesson and Bissell state that attempting to “graft” a public health mindset onto 273 
pharmacists, as required amid the current direction of role extension, 274 
operating within a commercial environment is, in their opinion, contradictory.29  275 
Indeed, the commercial nature of the sector may impact negatively on 276 
pharmacy’s reputation.  Companies are sensitive to public opinion and may 277 
react to please shareholders rather than patients.41 42     278 
 279 
The corporatization of the community pharmacy sector also impacts on the 280 
functions of the pharmacist.  The Royal Pharmaceutical Society of Great 281 
Britain (RPSGB – the professional and regulatory body for pharmacists in 282 
England, Scotland and Wales) has developed a number of initiatives (e.g. 283 
Pharmacy in a New Age – PIANA) aimed at developing the pharmacist’s 284 
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professional function.23  However, the rise of corporate pharmacies has made 285 
it increasingly difficult for the RPSGB to exert influence across the community 286 
pharmacy sector.  For example, despite concerns from within the profession 287 
that pharmacists are not being given adequate breaks during working hours, 288 
potentially leading to an increased number of dispensing errors, the RPSGB 289 
has proved ineffectual in ensuring its members have the working conditions 290 
and support necessary to promote and develop professional practice 291 
(although its ability to do so was seriously curtailed by defeat in the Jenkins 292 
Case of 1920 which, to a significant extent, prohibited it from representing the 293 
interests of its members).43-45  Taylor and Harding (2003) argue that the 294 
community pharmacy sector is characterized by a dualistic approach to 295 
service delivery: “corporate pharmacies maximize profit through economies of 296 
scale and rationalization, independents pursue profit maximization primarily by 297 
service delivery” (p143).14 298 
 299 
OBJECTIVES 300 
 301 
The aim of the research presented in this paper was to explore how the type 302 
of pharmacy in which pharmacists were employed (supermarket, multiple, 303 
large chain, small chain, independent) influenced the data collected under the 304 
following objectives: 305 
 306 
1. To describe the public health activities of UK community pharmacists in 307 
2006; 308 
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2. To explore the attitudes of community pharmacists towards pharmacy’s 309 
ability to compete effectively for funding to provide services that meet 310 
public health needs identified by local PCOs; and, 311 
3. To explore the attitudes of community pharmacists on the potential of 312 
various factors to act as barriers to the development of community 313 
pharmacy’s public health function. 314 
 315 
METHODS 316 
 317 
A survey design was considered a suitable strategy to explore various issues 318 
surrounding the development of the public health function of community 319 
pharmacists.  Initial interviews were conducted with six pharmacy and public 320 
health ‘key players’ identified during a comprehensive literature review.  321 
Based on the findings of the literature review and the initial interviews, a self-322 
completion postal questionnaire was developed.  This was piloted and 323 
administered to Directors of Public Health and Chief Pharmacists in all the 324 
PCOs of the UK (the results of this phase of the study are not discussed here 325 
but are available elsewhere).46 326 
 327 
This first questionnaire was then amended to reflect a community pharmacist 328 
population and piloted on a convenience sample of nine community 329 
pharmacists which reflected the breadth of community pharmacy practice (i.e. 330 
employed and self-employed pharmacists, pharmacists working in 331 
supermarket pharmacies, multiple pharmacies and independent pharmacies).   332 
 333 
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The questionnaire comprised four sections and contained a total of 17 334 
questions.  The first section concerned occupational details.  Respondents 335 
were asked to indicate which of the following titles most closely corresponded 336 
to the job they held during data capture: 337 
 338 
• Proprietor/owner 339 
• Manager 340 
• Relief pharmacist 341 
• Second pharmacist 342 
• Locum 343 
• Non-store based pharmacist 344 
• Other (respondents selecting this option were asked to specify their job 345 
title). 346 
 347 
This question was used to filter respondents to the appropriate part(s) of the 348 
questionnaire. 349 
 350 
In this section, respondents were also asked to indicate which type of 351 
pharmacy they had most regularly worked in during six months preceding data 352 
capture: 353 
 354 
• Supermarket 355 
• Multiple (200 outlets or more) 356 
• Large chain  (more than 20 outlets but less than 200) 357 
• Small chain (20 outlets or less but more than 5) 358 
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• Independent (5 outlets or less). 359 
 360 
The second section of the questionnaire focussed on “pharmacy public health 361 
activity” – i.e. health improving measures/schemes provided through 362 
community pharmacies.  A list of 18 different services (see Table 2)b, derived 363 
from the literature – most noticeably the two PharmacyHealthLink (a charity 364 
which advocates a greater role for pharmacy in public health) Evidence 365 
Bases47 48 – the preliminary exploratory interviews, and the pilot work was 366 
utilised.  Respondents were asked to select one of four possible options: 367 
 368 
• Yes (i.e. the service is being provided) 369 
• No (i.e. the service is not being provided) 370 
• Planned for the future (i.e. the pharmacy is planning to provide the 371 
service in the future) 372 
• I do not think that this is a public health role.  373 
 374 
Section three examined attitudes towards pharmacy’s involvement in public 375 
health, including opinions on recent pharmaceutical and NHS policy 376 
developments, and beliefs on advantages and disadvantages in the 377 
development of the public health function of community pharmacists.  In this 378 
section, community pharmacists were asked to indicate on a three-point scale 379 
(“pharmacy will”, “pharmacy may” and “pharmacy will not” – plus an “unsure” 380 
option) if they believed that community pharmacy would be able to compete 381 
effectively with other healthcare providers for access to funding to develop 382 
services that met public health needs identified by local PCOs. 383 
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 384 
A number of potential barriers to the development of the public health function 385 
associated with community pharmacy practice were identified from the 386 
literature and preliminary interviews, and further refined after the pilot study.  387 
In addition, respondents were given the opportunity to add “other” barriers as 388 
they saw fit.  The factors listed were: 389 
 390 
• Time constraints 391 
• Lack of available funding 392 
• Unsuitable premises 393 
• Lack of knowledge 394 
• Lack of training opportunities 395 
• Lack of understanding of public health 396 
• Lack of awareness of the social model of health 397 
• Unwillingness of pharmacists to leave the ‘comfort zone’ of dispensary 398 
• Conflicts arising from commercial interests 399 
• Pharmacy’s position on the fringes of the NHS 400 
• Lack of communication between pharmacy and other health 401 
professionals/PCOs 402 
• Ignorance of community pharmacy’s potential public health contribution 403 
at PCO level 404 
• Pharmacy’s inexperience of the commissioning process 405 
• Lack of a local, unified pharmacy organisation to bargain collectively for 406 
funding 407 
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• Inability of the Local Pharmaceutical Committee  (LPC) to represent 408 
pharmacy effectively 409 
• The removal of the obligation of PCOs to consult LPCs 410 
• Lack of incentive for employee pharmacists. 411 
 412 
Respondents were asked to indicate whether they thought the various factors 413 
constituted a “major” barrier, a “minor” barrier, or if the factor was “not a 414 
barrier” (they were also provided with the option of selecting an “unsure” 415 
option).  The internal consistency, measured using Cronbach’s alpha, of the 416 
scales used in this section was 0.81.  The exclusion of any of the items would 417 
not increase the alpha value (see Table 4). 418 
 419 
The final section of the questionnaire recorded demographic information about 420 
respondents.  Data collected were sex and age (respondents were provided 421 
with a “do not want to say” option for any details which they did not wish to 422 
impart).  Such background information helped to build a demographic profile 423 
of the respondents (to assess how representative of the study population the 424 
sample was) as well as allowing analysis of the effects of these variables on 425 
attitudes towards pharmacist involvement in public health. 426 
 427 
At the time of the study (August-October 2006) there were over 46,000 428 
pharmacists registered with the regulatory body for pharmacy and 429 
pharmacists in England, Scotland and Wales, the RPSGB.49  All pharmacists 430 
who wish to practice in the UK have to be on the RPSGB’s Register of 431 
Pharmaceutical Chemists, with the exception of pharmacists in Northern 432 
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Ireland (n≈1,800) who are registered with the Pharmaceutical Society of 433 
Northern Ireland (PSNI).50  It was decided to survey a proportionate stratified 434 
sample of 2000 practicing community pharmacists. 435 
 436 
The community pharmacist population was divided into strata – country of the 437 
UK and sex – and sampling from the strata was carried out using simple 438 
random sampling.  This guarded against obtaining an unrepresentative 439 
sample.  At this point the proposed sample still included pharmacists from 440 
Northern Ireland, however, these were later removed.a  The final sampling 441 
frame was designed to ensure proportionate representation of all the strata in 442 
the final sample with 84.17% (n=1683/2000) of the sample resident in 443 
England, 10.38% (n=208/2000) resident in Scotland and 5.45% (n=109/2000) 444 
resident in Wales, 47.1% (n=942/2000) being male and 52.9% (1058/2000) 445 
being female. 446 
 447 
Contact details for the 2000 practicing community pharmacists of the sample 448 
were sought from the RPSGB.  However, only 1998 labels (per set) were 449 
received.  The self-completion postal questionnaire was then administered to 450 
the sample (n=1998) with a follow-up to non-responders 4 weeks later.  451 
Returned questionnaires were checked for completeness.  Although some 452 
item non-response was apparent, the levels were insignificant and it did not 453 
appear that respondents had experienced any real difficulty in answering any 454 
of the questions.  Responses to closed questions were inputted into a 455 
bespoke database and analyzed in SPSS (version 12.0 for Windows).  The 456 
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final data set was screened for errors by frequency checks which revealed all 457 
coded values fell within the expected ranges.   458 
 459 
RESULTS 460 
 461 
A total of 1023 community pharmacists returned their questionnaire – an 462 
overall response rate of 51%.  Response was higher amongst the female 463 
subset of the sample (57%; n=597 returns/1056 possible returns) than the 464 
male subset (45%; n=426/942).  Respondents approximated to the 465 
proportions intended in the original sample with 85% (n=869/1023) of 466 
respondents being registered in England, 10 % (n=98/1023) in Scotland and 467 
5% (n=56/1023) in Wales. 468 
 469 
Women accounted for 58% (n=590/1023) of all survey respondents.  This 470 
figure is similar to the proportion of women (54%) on the Register of 471 
Pharmaceutical Chemists held by the RPSGB (figures obtained from 49).  472 
However, the most recent Pharmacy Workforce Census49 reported that 51% 473 
of the community pharmacy workforce (as opposed to the overall pharmacy 474 
workforce) were women. 475 
 476 
Nine percent (n=88/1014) of respondents were under the age of 29.  477 
However, around a fifth of all pharmacists (20%), and more specifically 478 
community pharmacists (19%), were under 29 in 2005.49  This suggests that 479 
pharmacists below the age of 29 were less likely to respond to the 480 
questionnaire.  Conversely, a quarter (25%, n=258/1014) of all respondents 481 
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were aged 50-59 compared to just 15% and 19% of all pharmacists and 482 
community pharmacists respectively.  Nine respondents chose not to indicate 483 
their age. 484 
 485 
The following section details selected results from the study.  A 486 
comprehensive report of all the findings of the wider research project is 487 
available elsewhere.46 488 
 489 
Service provision 490 
 491 
Community pharmacists were asked which ‘public health services’ were 492 
provided in the pharmacy in which they worked most regularly during the six 493 
months preceding the study. 494 
 495 
Analysis showed relationships (Chi square test (χ2) with Ρ≤0.05, “this is not a 496 
public health role” category excluded – owing to small number of respondents 497 
selecting this option – to ensure conditions of the test statistic were met) 498 
between the provision of 14 different services and the type of community 499 
pharmacy most regularly worked in (independent: number of outlets (n) ≤5, 500 
small chain: 5<n≤20, large chain: 20<n≤200, multiple: n≥200, and 501 
supermarket).  There was no relationship between the type of pharmacy 502 
worked in and the two essential services assessed namely health promotion 503 
on the premises and the collection of waste medicines.  Furthermore, there 504 
was no association between the provision of the sale of emergency hormonal 505 
contraception (a retail transaction) over the counter and the type of pharmacy 506 
 21
worked in.  Of the enhanced and ‘unspecified’ services assessed only the 507 
provision of minor ailments schemes showed no association with the type of 508 
pharmacy.  Where an association between provision and type of pharmacy 509 
was observed, the percentage of pharmacists reporting the provision of 510 
services, sub-divided by type of pharmacy is shown in Table 3. 511 
 512 
The ability of pharmacy to compete in a commissioning-led NHS 513 
 514 
Amid the climate of NHS reform pursued by New Labour, most pertinently the 515 
gradual transition of the NHS from a provider to a commissioner of healthcare 516 
with increasing scope for private sector provision, community pharmacists 517 
were asked if they believed that community pharmacy would be able to 518 
compete effectively with other healthcare providers for access to funding to 519 
develop services that met public health needs identified by local PCOs.  The 520 
type of pharmacy worked in most regularly during the six months preceding 521 
administration of the questionnaire influenced the attitudes of community 522 
pharmacists towards pharmacy’s ability to compete effectively for funding (χ2, 523 
Ρ=0.001).  Over a third of survey pharmacists working in small chains and 524 
independents (37% (n=21/57) and 33% (n=113/341) respectively) believed 525 
that pharmacy would not be able to compete effectively for funding.  This 526 
figure falls to below 25% (23% (n=15/65) supermarkets, 22% (n=21/97) large 527 
chains) for the corporate pharmacy chains (i.e. those in chains of 20 or more) 528 
and to 18% (n=62/353) for pharmacists employed most regularly in multiples 529 
(chains with 200 or more outlets). 530 
 531 
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Barriers to the development of the public health function of community 532 
pharmacists 533 
 534 
Respondents were asked their opinions on the potential of a variety of factors 535 
to act as barriers to the development of the public health function of 536 
community pharmacists.  Associations were observed between the type of 537 
pharmacy worked in and the reporting of the potential of three out of the 538 
seventeen listed factors to act as barriers to development. 539 
 540 
Pharmacists working most regularly in supermarkets (34%, n=22/64) and 541 
multiple pharmacy chains (41%, n=147/355) considered conflicts with 542 
commercial interests to be a more significant barrier than their colleagues 543 
working within small chains (23%, n=13/56) and independents (26%, 544 
n=89/336) (χ2, Ρ=0.000). 545 
 546 
Conversely, for factors relating to representation (weak Local Pharmaceutical 547 
Committee (LPC) – LPCs represent all NHS pharmacy contractors within a 548 
defined locality (χ2, Ρ=0.003) – and the removal of the obligation of the PCO 549 
to consult the LPC when developing new, potentially pharmacy-based, 550 
services (χ2, Ρ=0.035)), the opposite was observed.  Survey pharmacists who 551 
had worked in independents (53%, n=178/339 and 52%, n=170/330) most 552 
regularly in the six months preceding the study were more inclined to class 553 
these factors as major barriers than their counterparts in supermarkets (47%, 554 
n=30/64 and 39%, n=24/61) and multiples (49%, n=174/358 and 44%, 555 
n=154/350).   556 
 23
 557 
DISCUSSION 558 
 559 
Based on the reporting of respondents, supermarket pharmacies appeared to 560 
be less likely than small chains and independent pharmacies to provide a 561 
home delivery service and domiciliary visits.  Supermarkets also appeared to 562 
be less likely to provide emergency hormonal contraception (EHC) on a 563 
patient group direction (PGD), needle exchange schemes and the supervised 564 
administration of medicines (the most common medicines for which 565 
supervised administration is requested are used in the withdrawal treatment of 566 
drug addiction).   567 
 568 
It is of note that the delivery of medicines to patients’ homes offers no direct, 569 
short-term financial return and is operated primarily to both benefit patients 570 
and, hopefully, retain business in the long-term.  The provision of EHC and 571 
services for drug misusers are controversial to certain subsections of the UK 572 
population (not to mention pressure groups and the print media) which may 573 
deter commercial bodies, reliant as they are on the patronage of the general 574 
public, from offering such services.  This provides an example of the potential 575 
conflicts that can arise between operation in a commercial environment and 576 
the provision of professional services and adds weight to Denzin and Mettlin’s 577 
criticism that the commercial interests of pharmacists are inconsistent with the 578 
altruistic attitude of the service ideal of professions.35  One notable illustration 579 
of the commercial focus overriding the interests of patients was the decision of 580 
Tesco (the UK’s largest supermarket group) to stop supplying EHC to persons 581 
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under 16 years of age without a prescription in response to concerns 582 
expressed by some of their customers, thus highlighting the fact that 583 
companies have a significant responsibility to their shareholders – a 584 
responsibility that might not exist with individual professionals.42 51   585 
 586 
Another area where there appeared to be a particularly marked difference in 587 
levels of provision between the different types of pharmacy outlets were the 588 
screening services – cholesterol, diabetes and sexually transmitted infection 589 
(STI) testing.  Corporate pharmacies possess the financial power, by virtue of 590 
their large turnovers, to be able to subsidize provision of these services – 591 
which are unlikely to generate significant profits – than small chain and 592 
independent pharmacies which appeared less likely to engage in the provision 593 
of screening services. 594 
 595 
A larger proportion of supermarket and multiple pharmacies provided the only 596 
advanced service – Medicines Use Reviews (MURs) – than independents or 597 
small chains.  It is important to acknowledge that these were introduced as 598 
part of the new contract for England and Wales in April 2005, only shortly 599 
before the commencement of the research and as commercial organizations, 600 
pharmacies have to adapt to the market, and the greater capacity of multiples 601 
allows them to adapt to the contractual changes much more rapidly than 602 
independent pharmacies.  However in a further example of the low levels of 603 
professional autonomy afforded employee pharmacists, evidence is emerging 604 
of pharmacy companies pressuring pharmacists into conducting significant 605 
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numbers of MURs, even threatening disciplinary action if employee 606 
pharmacists fail to achieve the targeted number of MURs.52 607 
 608 
While it appears that service provision varies based on ownership, these 609 
variations have a number of possible explanations.  The variation could be 610 
dependent on the willingness of the contractors to offer the service, the ability 611 
– particularly in terms of capacity – of contractors to offer the service, or the 612 
appropriateness of the service for the location served by the pharmacy (i.e. 613 
there may be little call for a needle exchange scheme at an out-of-town 614 
supermarket pharmacy).  Regardless of the explanation(s), it does mean that 615 
changes in the balance and composition of the pharmacy market could impact 616 
upon service provision.  The exemptions to the Control of Entry Regulations 617 
introduced as a result of the OFT inquiry are beginning to have an impact (as 618 
can be seen in Figure 1).  The exemptions effectively allow any number of 619 
supermarkets, provided they meet the exemption for floor space, extended 620 
opening hours or both, to automatically obtain a contract to provide NHS 621 
pharmaceutical services without the requirement to prove that the pharmacy is 622 
either necessary or desirable for a given community.  The most conspicuous 623 
implication of this, as was recently highlighted by the Pharmaceutical Services 624 
Negotiating Committee (PSNC – the representative organization of community 625 
pharmacy on NHS matters) Chairman, is that less money is available for each 626 
contractor.53 627 
 628 
Under the contractual framework, local enhanced services, commissioned by 629 
PCOs, will inevitably lead to variations in service provision between localities 630 
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due to the differing health needs of local populations.  However, the results 631 
from this study suggest that variation in service provision through community 632 
pharmacy will also be observed between pharmacy outlets based on their 633 
ownership (i.e. supermarkets, multiples, independents etc.). 634 
 635 
Attitudinal elements of the survey suggested that community pharmacists 636 
believed that the larger pharmacy chains and supermarkets, in effect 637 
corporations with significant turnovers, would occupy a propitious position in 638 
terms of attracting finance to develop services.   639 
 640 
New Labour, consistent with its third way approach of avoiding socialist-style 641 
state intervention while ostensibly ameliorating the worst excesses of 642 
capitalism, has openly invited the private sector into the provision of NHS 643 
primary care services by virtue of the commissioning process.54  Pharmacy, 644 
as a private provider of NHS services operating on the interface between 645 
commerce and healthcare, would seem to be ideally placed to exploit these 646 
reforms.  Indeed, the seemingly unprecedented attention given to pharmacy in 647 
Department of Health (DoH) policy documents would suggest that the 648 
Government has identified pharmacy as a suitable partner.24-27  Furthermore, 649 
the multiples – with their capacity and responsiveness, allied to their 650 
widespread geographical coverage – are attractive to partners (e.g. the 651 
government) because of their national scope (organizing the provision of a 652 
service through a single partner provider with 1000 outlets across the country 653 
is considerably less complex than organizing provision of the service through 654 
1000 independent pharmacies).  For example, Boots, the UK’s second largest 655 
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pharmacy chain, was selected as the DoH’s preferred partner for Chlamydia 656 
screening through pharmacy which was piloted at all its London stores (over 657 
200) from November 2005.55 658 
 659 
Paradoxically, the results suggest that community pharmacists consider 660 
multiple pharmacy chains and supermarkets to have proportionally more 661 
outlets unsuitable for the provision of services specified by the new contract 662 
and that conflicts between patient care and commercial interests may be 663 
heightened within these pharmacies. 664 
 665 
Furthermore, the results suggest that community pharmacists feel that factors 666 
relating to representation and financing will disproportionately affect smaller 667 
chains (i.e. smaller chains will find it more difficult to access funding, perhaps 668 
in part because of the inability to bargain collectively brought about by 669 
removing the obligation of PCOs to consult LPCs).  Should the views of 670 
pharmacy owners and those working most regularly in small chain and 671 
independent pharmacy prove to be correct, the most salient implication of this 672 
is that, as highlighted previously, independent pharmacies will not be able to 673 
provide as comprehensive a range of services (including those services 674 
currently classified by the profession as ‘pharmacy-based public health 675 
services’) as the multiple chains and supermarket pharmacies. 676 
 677 
Logic suggests that large corporations, with their financial muscle, widespread 678 
geographical coverage and efficient marketing and public relations 679 
departments, may attract a disproportionate amount of income through 680 
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commissioning processes.  As chains of five pharmacies or less made up 681 
41% of the retail pharmacy sector in 2006/2007 this could have severe 682 
implications for service provision across the sector.5  If corporate pharmacy 683 
chains were to monopolize commissioning monies then the proportion of the 684 
global sum (total NHS funding for pharmacy) available to independents will be 685 
diminished; arguably hastening their demise.  Additionally, an inability to 686 
attract funding has the potential to stifle the professional development of 687 
community pharmacists employed within independent pharmacies who may 688 
find themselves providing only a limited range of routine services in 689 
comparison to their corporate colleagues. 690 
 691 
It is also worthy of note that independent pharmacies tend to be located in the 692 
heart of communities whereas supermarkets are more often found in out-of-693 
town retail developments which are difficult to access without a car.  694 
Independent pharmacies are more accessible to those without private 695 
transport, disproportionately those with lower incomes.7  Commissioning 696 
therefore has the potential to reinforce inequities in access to pharmacy-697 
based services with those without access to a car, predominantly the 698 
socioeconomically disadvantaged, unable to visit supermarket pharmacies 699 
without considerable difficulty and/or expense.  Furthermore, the 700 
corporatization of pharmacy may further reinforce these inequities by 701 
decreasing the numbers of independent pharmacies.  With the current 702 
economic climate favoring the larger pharmacy chains and the concentration 703 
of pharmacies in affluent areas at the expense of areas of economic 704 
deprivation, variability in service provision between pharmacy outlets may 705 
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further increase the inequalities in access identified by the Inverse Care Law, 706 
which, in its simplest form, prognosticates that those most in need of health 707 
care (disproportionately the socioeconomically disadvantaged) are those who 708 
are least likely to be able to access it (the role of the market in reinforcing this 709 
should also be highlighted). This is an area which demands further 710 
research.56-58 711 
 712 
While the data collected on service provision are robust, further research is 713 
recommended, in particular: 714 
 715 
• The longitudinal monitoring of service provision through community 716 
pharmacy to assess: 717 
o The effects of increased levels of primary care commissioning 718 
on service provision (particularly amongst the independent 719 
pharmacy sector); and, 720 
o Variations in service provision between the different types of 721 
pharmacy to ensure that service provision is adequate across 722 
the pharmacy network so as to avoid any inequities in access 723 
for the general public. 724 
 725 
The results of the study suggested several areas where further qualitative 726 
research is justified in order to provide a more nuanced understanding of the 727 
phenomena observed.  With commissioning being forced to the forefront of 728 
NHS reforms, in-depth study of the attitudes of stakeholders to pharmacy’s 729 
ability to compete for funding is merited.  The reasons why community 730 
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pharmacists displayed a lack of confidence in the ability of community 731 
pharmacy to compete effectively for funding were not examined.  Identification 732 
of such concerns may enable commissioning bodies to address these and 733 
promote greater engagement in the commissioning process by pharmacists, 734 
to the benefit of pharmacy itself, the NHS and the general public. 735 
 736 
LIMITATIONS 737 
 738 
Survey methodology, and the data collection instruments associated with 739 
them, possess inherent disadvantages and these are to be considered as 740 
limitations in this research.  Structured questionnaires largely contain pre-741 
coded response choices that may not be sufficiently comprehensive.59  More 742 
specifically, self-completion postal surveys do not allow for detection of 743 
ambiguities in, and misunderstanding of, the survey questions (although pilot 744 
studies aimed to negate these possibilities).60  There is no guarantee that the 745 
questions have been completed honestly and there is also likely to be a social 746 
desirability response bias – people responding in a way that shows them in a 747 
good light.60 61 748 
 749 
Postal questionnaires tend to yield low response rates but the response rate 750 
to the questionnaire was satisfactory.  This may be explained by the subject 751 
matter being of interest to respondents and the relatively high profile of public 752 
health at the time of the study.  A further limitation of this research is the 753 
limited evidence-base available for consultation when designing the 754 
questionnaire.  However, the preliminary interviews and the available literature 755 
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were used to inform the design of the questionnaire which was further refined 756 
as the research progressed. 757 
 758 
A final point concerns questionnaire non-response.  Ideally non-responders 759 
would have been contacted to ascertain reasons for non-response.  Such data 760 
would have been useful to assess potential bias introduced into results as a 761 
result of certain characteristics of the respondents (i.e. did some members of 762 
the sample fail to return questionnaires because they were offended by a 763 
certain question/the questionnaire?).  However, owing to time constraints, 764 
ethical approval limitations and data protection restrictions this was not 765 
possible.   766 
 767 
CONCLUSIONS 768 
 769 
The results of this study indicate that the provision of pharmacy-based public 770 
health services varies based on pharmacy ownership.  The decreased levels 771 
of provision of certain services in certain types of pharmacy highlights 772 
potential conflicts between patient care and commercial interests.  773 
Furthermore, attitudes towards pharmacy’s ability to compete effectively for 774 
funding to develop services, and the barriers to the development of the public 775 
health function, suggest that community pharmacists believe that corporate 776 
pharmacy chains may attract a disproportionate amount of financing from 777 
NHS commissioning processes. 778 
 779 
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A mixed market in community pharmacy may be required to maintain a 780 
comprehensive range of pharmacy-based public health services and, in turn, 781 
provide maximum benefit to all patients.  The increased commissioning 782 
activity of NHS PCOs, allied to the increasing corporatization of community 783 
pharmacy may promote the maldistribution of health improvement/harm 784 
reduction services through community pharmacy in the UK.  Longitudinal 785 
monitoring of service provision is recommended to ensure that service 786 
provision is adequate across the pharmacy network. 787 
788 
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TABLES 940 
 941 
Table 1 Examples of public health roles for pharmacists (after Walker40) 942 
 943 
• Provide advice on self-care • Provide unplanned teenage 
pregnancy support 
• Provide advice to young mothers • Support patients with chronic illness 
• Provide support to develop effective 
parenting skills 
• Provide advice on how medicines 
work 
• Participate in health promotion 
campaigns 
• Maintain patient medication records 
• Promote drug misuse awareness • Promote patient medication 
awareness 
• Participate in needle exchange 
schemes 
• Provide out-of-hours services 
• Promote healthy schools • Provide collection and delivery 
services 
• Improve AIDS awareness • Undertake domiciliary visits  
• Provide sexual health support • Facilitate disposal of waste medicines 
 944 
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 946 
Table 2 Services included in the study 947 
 948 
Service Classification under 2005 Pharmacy Contract 
Collection of waste medicines Essential Health promotion (HP) on premises 
Medicines Use Reviews (MURs) Advanced 
Supervised administration of medicines 
Enhanced 
Smoking cessation 
The supply of EHC on a patient group direction 
(PGD) 
Minor ailments scheme 
Needle exchange 
Palliative care services 
Out of hours services 
The supply of emergency hormonal 
contraception (EHC) over the counter (OTC) Retail transaction
a
 
Diabetes testing 
Services not specified in the terms of the contract 
but provided through certain pharmacies 
Cholesterol testing 
Blood Pressure (BP) testing 
Sexually transmitted infection (STI)  testingb 
Domiciliary visits 
Home delivery of medicines 
HP off premises 
 
 
a
 The retail supply of EHC was included for assessment owing to the additional level of 
pharmacist involvement in these supplies (the pharmacist must assess the suitability of 
the supply to the patient and provide an additional level of counseling in comparison to 
the vast majority of ‘P’ medicine sales) and the focus given to pharmacy’s role in 
reducing teenage pregnancy in policy documents. 
 
b
 It should be noted that the multiple pharmacy chain Boots was selected as the 
Department of Health’s preferred partner for Chlamydia screening through pharmacy 
which was piloted at all its London stores (over 200) from November 2005. 
 949 
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 951 
Table 3 Reporting of the provision of public health services through the different types of 952 
community pharmacy by survey pharmacists 953 
 954 
 Percentage of respondents working most regularly in each type 
of pharmacy who reported provision of the service 
Total 
(%) Ρ Supermarket  
(max n=65) 
Multiple 
(max 
n=360) 
Large 
chain 
(max 
n=97) 
Small 
chain 
(max 
n=59) 
Independent 
(max n=346) 
Home delivery 28.8 75.4 93.6 92.9 88.4 80.7 0.000 
Supervised 
administration of 
medicines (i.e. 
methadone) 
54.4 78.1 76.1 77.2 61.4 70.3 0.000 
Smoking cessation 60.7 66.2 64.9 64.9 75.3 69.1 0.035 
Medicines use 
reviews 75.0 78.1 68.1 50.0 55.7 66.9 0.000 
The supply of 
emergency 
hormonal 
contraception on a 
patient group 
direction 
36.4 50.0 43.8 52.7 50.8 48.8 0.050 
Blood pressure 
testing 64.4 44.3 39.1 26.4 42.9 43.5 0.000 
Needle exchange 5.7 30.4 33.3 38.5 32.4 30.9 0.021 
Palliative care 19.2 21.0 32.9 30.4 33.6 27.7 0.000 
Out of hours 28.3 22.1 17.9 20.8 30.0 25.6 0.000 
Domiciliary visits 5.9 19.1 19.5 33.3 37.4 25.0 0.032 
Diabetes testing 23.1 31.0 19.8 13.7 20.3 24.0 0.000 
Cholesterol testing 3.8 36.5 13.8 15.1 15.6 23.5 0.000 
Health promotion off 
of the pharmacy 
premises 
7.8 9.0 8.6 6.4 14.5 10.9 0.016 
Sexually transmitted 
infection testing 2.0 11.0 1.3 6.1 3.1 6.3 0.001 
 955 
956 
 40
Table 4 Results of the internal consistency analysis between items  957 
 958 
Barrier Cronbach’s alpha value if the item is excluded 
Time constraints 0.81 
Lack of available funding 0.81 
Unsuitable premises 0.81 
Lack of knowledge 0.80 
Lack of training opportunities 0.80 
Lack of understanding of public health 0.80 
Lack of awareness of the social model of health 0.80 
Unwillingness of pharmacists to leave the ‘comfort zone’ of 
dispensary 0.80 
Conflicts arising from commercial interests 0.80 
Pharmacy’s position on the fringes of the NHS 0.80 
Lack of communication between pharmacy and other health 
professionals/PCOs 0.80 
Ignorance of community pharmacy’s potential public health 
contribution at PCO level 0.80 
Pharmacy’s inexperience of the commissioning process 0.79 
Lack of a local, unified pharmacy organisation to bargain 
collectively for funding 0.79 
Inability of the Local Pharmaceutical Committee  (LPC) to 
represent pharmacy effectively 0.79 
The removal of the obligation of PCOs to consult LPCs 0.80 
Lack of incentive for employee pharmacists 0.80 
 
 
Cronbach’s alpha = 0.81 
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FIGURE LEGENDS 961 
 962 
Figure 1 Number of community pharmacies in England and Wales from 1994-95 to 2006-07 963 
 42
 964 
